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DOI 10.1016/j.ccr.2009.11.020SUMMARYWe hypothesized that DNA methylation distributes into specific patterns in cancer cells, which reflect critical
biological differences. We therefore examined the methylation profiles of 344 patients with acute myeloid
leukemia (AML). Clustering of these patients by methylation data segregated patients into 16 groups. Five
of these groups defined new AML subtypes that shared no other known feature. In addition, DNA methylation
profiles segregated patients withCEBPA aberrations from other subtypes of leukemia, defined four epigenet-
ically distinct forms of AML with NPM1 mutations, and showed that established AML1-ETO, CBFb-MYH11,
and PML-RARA leukemia entities are associated with specific methylation profiles. We report a 15 gene
methylation classifier predictive of overall survival in an independent patient cohort (p < 0.001, adjusted
for known covariates).INTRODUCTION
Acutemyeloid leukemia (AML) is a highly heterogeneous disease
from the biological and clinical standpoint. This remains a signif-
icant barrier toward the development of accurate clinical classi-
fication, risk stratification, and targeted therapy of this disease.
Epigenetic control of gene expression has been suggested to
play a pivotal role in determining the biological behavior of cells.
One such epigenetic mechanism is DNA cytosine methylation,
which can alter gene expression by creating new binding sites
for methylation-dependent repressor proteins (Jones et al.,
1998; Nan et al., 1998), or by disrupting the ability of transcriptionSIGNIFICANCE
We show that large-scale genome-wide DNA methylation p
patterns in AML and identifies novel, biologically and clinically
strate that despite these distinct patterns, a set of genes can
silenced in AML versus normal controls, indicating their likely in
transformation process. Finally, we describe a 15 gene DNA me
independent cohort of patients and validated as an independ
potential of epigenetic markers for use even in patients for whfactors to bind to their target sequences (Kanduri et al., 2000;
Watt and Molloy, 1988). In normal development, the proper
distribution of DNA methylation plays a critical role in tissue
differentiation and homeostasis (Li et al., 1992; Okano et al.,
1999). Disruption of normal DNA methylation distribution is a
hallmark of cancer and can play critical roles in initiation,
progression, and maintenance of the malignant phenotype. For
example, aberrant hypermethylation and silencing of certain
tumor suppressor genes such as p15CDKN2B has been widely
reported in leukemias and other myeloid neoplasms (Cameron
et al., 1999; Christiansen et al., 2003; Shimamoto et al., 2005;
Toyota et al., 2001). We recently showed that hypermethylationrofiling reveals the existence of distinct DNA methylation
relevant defined AML subgroups. Additionally, we demon-
be identified that is consistently aberrantly methylated and
volvement as a common epigenetic pathway in the leukemic
thylation classifier capable of predicting overall survival in an
ent risk factor in a multivariate analysis, demonstrating the
om clinical biomarkers are not currently available.
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Table 1. Patient Characteristics
Gender Total (%)
Male 188 (54)
Female 156 (46)
Age Total (%)
< 60 years 294 (85%)
> 60 years 50 (15%)
Median years (range) 48 (15-77)
FAB Total (%)
M0 12 (3.5%)
M1 75 (21.8%)
M2 82 (23.8%)
M3 9 (2.6%)
M4 65 (18.9%)
M5 70 (20.3%)
M6 3 (0.87%)
NA* 28 (8.1%)
Cytogenetics Total (%)
inv(16)/t(16;16) 30 (9%)
t(8;21) 24 (7%)
t(15;17) 10 (3%)
t(9;22) 2 (0.6%)
t(6;9) 3 (0.9%)
t(v;11q23) 13 (3.8%)
3q abnormalities 2 (0.6%)
del5(q)/del7(q) 19 (5.5%)
Trisomy 8 14 (4%)
del9q 8 (2.3%)
Complex 8 (2.3%)
Normal 152 (44%)
Other 43 (12.5%)
NAa/Failure 13 (3.8%)
Cytogenetic risk Total (%)
Favorable 53 (15%)
Intermediate 231 (67%)
Unfavorable 47 (14%)
NAa 14 (4%)
CEBPA abnormalities Total (%)
Double mutation 24 (7%)
Single mutation 11 (3.1%)
Silenced 8 (2.4%)
Wild-type 301 (87.5%)
NPM1 mutation Total (%)
Negative 239 (69.5%)
Positive 105 (30.5%)
FLT3-ITD Total (%)
Negative 248 (72%)
Positive 96 (28%)
Table 1. Continued
EVI1 abnormalities Total (%)
Negative 317 (92%)
Positive 27 (8%)
For more patient details, please see Table S1.
aNA, not available.
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DNA Methylation Profiles in AMLand silencing of the master regulatory transcription factor
CEBPAwas associatedwith a leukemia entity with T cell/myeloid
features, hypermethylation of a number of additional transcrip-14 Cancer Cell 17, 13–27, January 19, 2010 ª2010 Elsevier Inc.tional regulators, and distinctive biological features (Figueroa
et al., 2009b; Wouters et al., 2007).
Based on these data, we hypothesized that DNA methylation
distributes into specific patterns in cancer, and that these meth-
ylation profiles impose and reflect critical biological differences
with practical clinical and therapeutic implications. In order to
test this hypothesis, we performed a comprehensive exploration
of DNA patterning in human disease, focusing on a well-charac-
terized cohort of 344 patients with AML.RESULTS
AML Is Composed of Epigenetically Distinct Diseases
Because the molecular heterogeneity of AML remains only
partially resolved, the first goal of our study was to determine
whether DNA methylation profiling could identify new clinically
and biologically relevant disease subtypes. For that purpose,
blast cells of 344 newly diagnosed AML patients were subjected
to DNA methylation profiling of over 50,000 CpG dinucleotides
containedwithin14,000 unique gene loci using theHELP (HpaII
tiny fragment enrichment by ligation-mediated PCR) method
(Figueroa et al., 2009a; Khulan et al., 2006). Table 1 summarizes
patients’ characteristics. DNA methylation measured by HELP
was highly concordant with a quantitative single locus DNA
methylation validation assay (correlation coefficient r = 0.88)
in these AML patients (see Figure S1A available online). An unsu-
pervised analysis using hierarchical clustering (1 - Pearson
correlation distance and Ward’s clustering method) showed
that leukemias could be distinctly grouped according to their
methylation profiles. A cut-off of 16 clusters was selected for
further analysis since this segregation most accurately overlap-
ped with the currently known molecular subtypes of AML while
at the same time revealing the existence of additional epigenetic
differences among the remaining patients. The stability of these
clusters was verified by performing comparison of multiple
cluster analyses using a decreasing number of probe sets (based
on alternative cutoffs of across-patient standard deviation,
Figures S1B–S1E). Table 2 shows the clinical, cytogenetic, and
molecular features of each of the 16 clusters. Three of these
patient clusters correspond to AML subtypes defined by the
World Health Organization classification (WHO, 2008) (Figure 1),
another eight clusters were enriched for cases harboring specific
genetic or epigenetic lesions, and the remaining five clusters
could not be explained by any known morphologic, cytogenetic,
or molecular feature. Each of these DNA methylation-defined
AML subtypes displayed a unique epigenetic signature when
compared with normal bone marrow CD34+ cells (Figure 2 and
Tables S3A–S3P). Taken together, these data indicate that
DNA methylation is not randomly distributed in AML blasts but
rather is organized into highly coordinated and well-defined
Cancer Cell
DNA Methylation Profiles in AMLpatterns. In most cases the AML subgroups showed a very
strong hypermethylation signature as compared with normal
marrow CD34+ cells. In contrast, a few of the clusters were
hypomethylated in comparison to normal controls. This distinc-
tive patterning is highly suggestive of a biologically significant
role for altered DNAmethylation in these different AML subtypes.
The data also suggest that the most prevalent tumor-associated
abnormality in gene promoter DNAmethylation abundance is not
always hypermethylation but can also be hypomethylation.
Cytogenetically Defined AML Subtypes Have Unique
Epigenetic Signatures
The WHO classification of AML defines cases with t(8;21),
inv(16), and t(15;17) translocations or the presence of the rele-
vant fusion genes as separate entities indicative of a favorable
clinical prognosis (WHO, 2008; Bloomfield et al., 1998; Grim-
wade et al., 1998). All three of these AML subtypes presented
with a unique methylation profile. Methylation cluster 1 (n = 26)
consisted entirely of cases carrying either inv(16) or t(16;16)
(22/26 cases), or the CBFB-MYH11 fusion gene (4/26). Methyla-
tion cluster 3 was significantly enriched for cases positive for
t(8;21) (22/31 cases, Fisher’s exact test p value < 1.85 E25),
and all cases in methylation cluster 6 carried the t(15;17) or the
PML-RARA fusion gene (8/8 cases). Patients in the two core
binding factor clusters did not further segregate according to
cKit mutation status, indicating that the presence of this muta-
tion does not result in a specific DNAmethylation pattern. Super-
vised analysis comparing each of these clusters to a cohort of
normal CD34+ cells from healthy donors revealed that they all
exhibited a unique signature, with a strong shift toward genes
being methylated in the AML subtypes compared with CD34+
normal marrow blasts. (Figure 2 and Table S3). The data are
consistent with a scenario whereby each of these fusion onco-
proteins can drive epigenetic patterning in hematopoietic cells,
and/or cooperate to drive leukemogenesis when specific sets
of complementary genes are deregulated through aberrant
DNA methylation.
Cluster 3 included nine cases that did not present with the
t(8;21) orAML1-ETO fusion gene, yet the survival curves of these
patients were indistinguishable from the 22 t(8;21) positive
patients in cluster 3 (log rank test, p value = 0.83). This finding
reflects the ability of DNAmethylation profiles to identify a subset
of patients with comparable risk and epigenetic patterning to
that of t(8;21) patients despite their lack of the aberrant AML1-
ETO fusion gene. Even though the number of patients is small,
the robustness of this common epigenetic profile is reflected in
the fact that these patients all continue to cluster together even
when different numbers of probe sets are used in the analysis
(Figures S1B–S1E). Furthermore, unsupervised analysis of these
patients using gene expression data failed to segregate them ac-
cording to the presence or absence of the t(8;21) (Figure S1F).
Epigenetic Differences Define NPM1-Mutated,
CEBPA-Mutant, and CEBPA-Silenced AMLs
Methylation profiling defined 13 additional AML subtypes. Four
of those methylation clusters (clusters no. 12, 13, 14, and 16)
were all significantly enriched for cases carrying NPM1 muta-
tions (Bonferroni adjusted Fisher’s exact test p values:
< 0.0008, < 9.4 E14, < 0.02, and < 0.048, respectively). Muta-tions in exon 12 of theNPM1 gene, which result in aberrant cyto-
plasmic localization of the protein, constitute an independent
favorable prognostic marker in AML (Falini et al., 2005).
However, when this mutation occurs in the context of an associ-
ated FLT3-ITD, then this favorable prognostic impact is lost
(Thiede et al., 2006). The NPM1 mutant clusters 12 and 13
were enriched for characteristic morphological subtypes, i.e.,
FABM1/M2 (11/12) andM4/M5 (34/45), respectively. The variety
of NPM1 methylation clusters could not be explained solely by
the presence or absence of concurrent FLT3-ITD (Table 2).
Although the four clusters were all enriched for NPM1mutations,
they still presented enough unique characteristics to separate
into 4 methylation clusters, each of them with a specific aberrant
DNA methylation signature (Figure 2 and Table S3). Differential
methylation in cluster 12 consisted almost entirely of hyperme-
thylated genes, whereas aberrant DNA methylation in the
remaining NPM1 clusters was more evenly distributed between
hyper- and hypomethylation when compared with normal
controls. These data support the notion that NPM1 mutations
play a dominant role in definingAMLbiology, but can bemodified
to a significant extent by additional alterations in epigenetic or
unidentified genetic factors. A significant difference in overall
survival was observed for the NPM1 clusters 12, 13, 14, and 16
(log rank test, p = 0.02), when compared with clusters 1, 3, and
4, which contained patients with inv(16), t(8;21), and CEBPA
double mutations (CEBPA-dm), respectively (Figure 3A). These
differences in survival remained significant after adjustment for
age, cytogenetic risk, NPM1 mutation, and FLT3-ITD mutation
status following multivariate analysis (Figure 3B).
The CEBPA transcription factor is a critical mediator of hema-
topoietic cell differentiation (Mueller and Pabst, 2006), and
CEBPA-dm AMLs are associated with a favorable clinical prog-
nosis (Wouters et al., 2009). These cases split into two distinct
subtypes with different methylation signatures. Methylation
cluster 4 displayed a markedly hypermethylated profile and
consisted entirely of CEBPA-dm cases (n = 14; Fisher’s exact
test p < 6.88 e-19). The clinical outcome of cluster 4 patients
was even better than the known favorable risk core-binding
factor leukemias, i.e., t(18;21) and inv(16) (2-year overall survival
± standard error [SE]; 78.6% ± 11.0%) (Figure 3A). DNA methyl-
ation cluster 9 was also significantly enriched for CEBPAmutant
cases (n = 7/9, Fisher’s exact test p < 0.000009), most of which
(5/7) harbored CEBPA double mutations. However, the cluster
9 signature was predominantly hypomethylated versus controls,
suggesting that these CEBPA-related leukemias are biologically
distinct from theCEBPA-dm cluster 4. Cluster 9 contained insuf-
ficient numbers to allow for a comparative survival estimate.
Five of the six patients in cluster 10 had previously been shown
to display a phenotype featuring CEBPA hypermethylation and
silencing (CEBPAsil), a hypermethylated gene profile, but with hy-
pomethylation of certain T cell genes, T cell lineage infidelity, and
poor clinical outcome (Figueroa et al., 2009b; Wouters et al.,
2007). The remaining patient in this cluster 10 had not previously
been recognized as a CEBPAsil leukemia (case 5360), but was
demonstrated upon further investigation in this study to indeed
display all the characteristic features of CEBPAsil leukemias
(Figure S2 and data not shown). Mutations or silencing ofCEBPA
thus appear to result in or to be associated with three epigenet-
ically distinct forms of leukemia.Cancer Cell 17, 13–27, January 19, 2010 ª2010 Elsevier Inc. 15
Table 2. Summary of Clinical, Cytogenetic and Molecular Features of the 16 DNA Methylation Clusters
Cluster No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Total
N 26 55 31 14 34 8 31 24 9 6 9 12 45 18 12 10 344
Clinical Markers
Gender
Male 12 36 22 8 19 4 17 12 5 4 5 6 25 6 4 3 188
Female 14 19 9 6 15 4 14 12 4 2 4 6 20 12 8 7 156
Age
<60 yr 24 37 29 13 27 8 25 20 8 6 9 11 43 16 10 8 294
>60 yr 2 18 2 1 7 0 6 4 1 0 0 1 2 2 2 2 50
FAB
M0 0 6 0 0 3 0 0 0 0 2 0 0 0 0 0 1 12
M1 0 9 6 10 6 0 21 4 2 3 0 5 2 4 2 1 75
M2 0 13 20 3 11 0 5 6 2 0 0 6 6 3 5 2 82
M3 0 0 1 0 1 7 0 0 0 0 0 0 0 0 0 0 9
M4 23 8 3 1 2 1 1 7 1 0 0 0 8 4 3 3 65
M5 3 6 1 0 7 0 4 3 0 0 9 1 26 6 2 2 70
M6 0 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 3
NA 0 12 0 0 4 0 0 4 4 1 0 0 2 0 0 1 28
Cytogenetic Markers
Cytogenetic class
inv(16)/t(16;16) 26a 2 1 0 1 0 0 0 0 0 0 0 0 0 0 0 30
t(8;21) 0 0 22 0 0 0 1 0 0 0 0 0 0 1 0 0 24
t(15;17) 0 0 1 0 1 8b 0 0 0 0 0 0 0 0 0 0 10
t(9;22) 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 2
t(6;9) 0 0 0 0 0 0 0 2 0 0 0 0 1 0 0 0 3
t(v;11q23) 0 0 0 0 0 0 0 5 0 0 6 1 0 1 0 0 13
3q 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 2
del5(q)/del7(q) 0 12 1 0 1 0 1 1 0 1 0 0 0 0 1 1 19
tri8 0 1 0 0 0 0 2 2 1 0 1 0 5 1 0 1 14
del9q 0 1 0 3 2 0 1 0 1 0 0 0 0 0 0 0 8
Complex 0 3 1 0 1 0 0 1 0 2 0 0 0 0 0 0 8
Normal 0 17 4 10 19 0 17 10 6 1 1 7 33 11 8 8 155
Other 0 13 0 1 5 0 7 3 0 2 0 3 2 4 3 0 43
NA/Failure 0 0 1 0 3 0 1 1 1 0 1 1 4 0 0 0 13
Cytogenetic risk
Favorable 20 1 24 0 2 5 1 0 0 0 0 0 0 0 0 0 53
Intermediate 6 32 4 14 25 3 27 15 8 3 6 10 41 17 11 9 231
Unfavorable 0 22 2 0 3 0 2 8 0 3 2 1 1 1 1 1 47
Molecular Markers
CEBPA
Double mutant 0 0 2 14 0 0 0 0 5 0 0 0 0 0 3 0 24
Single mutant 0 3 1 0 1 0 2 0 2 0 0 0 1 1 0 0 11
Silenced 0 3 0 0 0 0 0 0 0 6 0 0 0 0 0 0 9
Wild-type 26 49 28 0 33 8 29 24 2 0 9 12 44 17 9 10 300
NPM1
Wild-type 26 54 30 14 26 8 17 13 7 6 9 2 8 7 9 3 239
Mutated 0 1 1 0 8 0 14 11 2 0 0 10 37 11 3 7 105
FLT3-ITD
Negative 26 45 28 12 28 4 18 15 7 6 9 4 21 11 9 5 248
Positive 0 10 3 2 6 4 13 9 2 0 0 8 24 7 3 5 96
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Table 2. Continued
Cluster No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Total
EVI1
Negative 26 42 31 14 31 8 30 17 9 6 8 12 45 16 12 10 317
Positive 0 13 0 0 3 0 1 7 0 0 1 0 0 2 0 0 27
NA, not available. Cytogenetic class is defined in order of importance according to the 1999 WHO classification (Harris et al., 1999): t(8;21), inv(16),
t(15;17), Complex (>3 clonal abnormalities), del5(q)/del7(q), 3q indicates any abnormality involving 3q, t(6;9), t(9;22), 11q23 indicates any abnormality
involving 11q23, tri8 indicates trisomy 8, del9q, NN indicates no abnormalities in karyotype, Other indicates that it does not classify in any other group.
For complete cytogenetic andmolecular information for each patient, see Tables S1 and S2. Also, see Figure S2 forCEBPAmethylation status of case
5630, which is in cluster 10.
a including four inv(16) cases detected by CBFB-MYH11 fusion gene PCR.
b including three t(15;17) cases detected by PML-RARA fusion gene PCR.
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of (Cyto)genetically Defined AML Subtypes
Methylation clusters 2, 5, 7, 8, and 15were defined solely by their
DNA methylation profiles and could not be explained by the
enrichment of any currently known recurrent cytogenetic, molec-
ular, or clinical feature (Table 2). Each of these AML subtypes
displays a unique and significant epigenetic signature versus
normal CD34+ controls (Table S3). Normal cytogenetics AML
cases were distributed among all five clusters, and although 5
of 24 cases in cluster 8 harbored 11q23 abnormalities, this was
not a defining feature of the cluster because it represented only
20.8% of the cases. Gene expression profiles of each of these
epigenetically defined clusters were obtained in a supervised
analysis comparing them with a set of normal CD34+ controls.
Each of the five clusters presented with a distinct gene expres-
sion profile. Figure 4A shows the top-scoring networks associ-
ated with each of these expression signatures. Aberrantly ex-
pressed genes far exceeded and only partially overlapped with
the aberrantly methylated genes in each cluster, which suggests
that even relatively small changes in epigenetic patterns can
have a significant biological impact in the cell. In order to deter-
mine the biological impact of this epigenetic deregulation, we
performed an integrative pathway analysis of the combined
aberrantly methylated and aberrantly expressed genes. This
analysis revealed that each of these clusters resulted in deregu-
lation of different canonical pathways. Cluster 5 showed deregu-
lation of immunity-related pathways, involving immunodefi-
ciency signaling, cytotoxic T-cell-mediated apoptosis, and
T cell receptor signaling. Cluster 2, on the other hand, was the
only one that significantly deregulated p53 signaling. Clusters 8
and 15 showed predominant deregulation of pathways involved
in molecular mechanisms of cancer, deregulating genes in the
DNA damage repair mechanism such as ATM, CHK1, MDM2,
and FANCD2, genes involved in cell-cycle regulation such as
CDK4 and CYCLIN D, as well as genes from the AKT signaling
pathway (Figure 4B). Most notably, a significant difference in
survival was observed between these novel AML subtypes. For
instance, clusters 5 and 7 correlated with an evidently better
outcome (2 year overall survival ± SE; 58.8% ± 8.4% and
45.2% ± 8.9% for clusters 5 and 7, respectively, versus 23.6%
± 5.7%, 26.4% ± 9.2%, and 33.3% ± 13.6%, for clusters 2, 8,
and 15, respectively) (log rank test, p = 0.04). After adjustment
for age, cytogenetic risk, NPM1 mutation, and FLT3-ITD muta-
tion status in a multivariate Cox proportional hazards regression
model including all the clusters with at least ten patients, four ofthe five novel clusters presented a statistically significant
increased hazard ratio with respect to the favorable risk inv(16)
cluster, whereas cluster 5 did not reach statistical significance
(Figure 3B). Epigenetic profiling thus identified a clinically rele-
vant and significant difference among AML subtypes not
captured by other methodologies.
AMLs Present a Common Epigenetic Signature
of Consistently Aberrantly Methylated Genes
Although the above studies were geared toward finding the
unique signatures of epigenetically defined AML subtypes, we
also wondered whether a set of genes could be defined whose
DNA methylation was consistently deregulated across all the
AML subtypes. We indeed identified a common aberrant DNA
methylation signature consisting of 45 genes, most of them
hypermethylated, that was consistently detected in at least 10
of the 16 clusters’ methylation signatures and affecting at least
70% of the cases studied (Figure 5A). Genes in this signature
are likely to be part of a common epigenetic pathway involved
in leukemic transformation of hematopoietic cells. Among these
genes we found the tumor suppressor PDZD2, transcriptional
regulators (ZNF667, ZNF582, PIAS2, CDK8), nuclear import
receptors (TNPO3, IPO8), and CSDA, a repressor of GM-CSF.
A complete list of the genes in this common signature is found
in Table S4.
We next looked at the gene expression levels of these genes
on Affymetrix HGU133 Plus 2.0 microarrays performed on the
same patients (Verhaak et al., 2009), and compared them with
those of a cohort of normal CD34+ bone marrow cells. Eight of
45 genes had to be excluded from the analysis due to failure
of the gene expression probe sets (n = 6) or because of lack of
representation of the transcript of interest on the expression
arrays (n = 2). For the remaining 37 genes, in all but 5 we found
either complete silencing or downregulation of the correspond-
ing transcript. Eighteen of these showed the expected differen-
tial gene expression when compared with normal CD34+ cells
(analysis of variance [ANOVA] followed by Dunnett’s test
p < 0.05) (Figure 5B). Four bidirectional promoters showed
silencing of one transcript with high expression of the transcript
from the opposite strand. The remaining genes were silenced in
both the AMLs and the normal CD34+ cells. The latter might be
explained, as we have previously shown, by the relative insensi-
tivity of gene expression microarrays to detect differential gene
expression of low-abundance transcripts, which can be over-
come by looking at the more sensitive epigenetic marksCancer Cell 17, 13–27, January 19, 2010 ª2010 Elsevier Inc. 17
Figure 1. DNA Methylation Segregates AML Patients into 16 Groups
Heatmap representation of a correlationmatrix in which each patient’s DNAmethylation profile is correlatedwith that of the other patients in the data set. Patients
are ordered according to the unsupervised analysis (hierarchical clustering) results, so that highly correlated patients are located next to each other. Parallel bars
on the right of the heatmap have been used to indicate the principal cytogenetic and molecular findings for each patient. Cluster membership and cluster feature
summaries are described on the left of the heatmap. Additional information is shown in Figure S1.
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DNA Methylation Profiles in AML(Figueroa et al., 2008). Alternatively, this finding could reflect the
establishment of a more irreversible state of silencing of these
genes in the AML blasts compared with the normal CD34+ cells.
A DNA Methylation Classifier Predicts Clinical Outcome
in AML
The fact that aberrant DNAmethylation of gene promoters repre-
sents an epigeneticmodification that is stably transmitted among
leukemic blasts and that this is done in an organized pattern that
correlates with disease subtypes led us to explore its potential as
predictor of important clinical features. Moreover, because DNA
is relatively stable in clinical samples andDNAmethylation is easy
to measure, it is very likely that small sets of methylated genes
could readily be harnessed as clinically useful biomarkers. There-
fore, in order to determine whether we could identify and validate
methylation biomarkers of independent prognostic value in AML,
we applied a three-step approach of model development and
validation. The complete patient cohort was randomly divided
into a training set (n = 200), a test set (n = 95), and an independent
validation set (n = 49). Cluster membership was not taken into
consideration for this part of the analysis. Using the supervised
principal components (SuperPC) method of Bair and Tibshirani
(2004), a Cox proportional hazards regression model for overall
survival was trained with data in the training set (see Supple-
mental Experimental Procedures). Parameters of the model
were chosen so that they maximized performance, as estimated
by 10-fold cross-validation on the training set. The model result-
ing from the maximum cross-validation performance estimate
was tested on the test set, found predictive, and used to predict
survival status on the independent validation set (Figure 6A). This
model included 18 probe sets, corresponding to 15 genes. The
predictor model included transcription factors (E2F1, ZFP161),
genes related to protein metabolism (USP50, SRR, PRMT7,
GALNT5), regulation of telomeres (SMG6), and signaling
(CXCR5, LCK) (see Table S5 for the complete list of features
used in this model). The predictive performance of this model
was validated on the 49-patient independent validation set both
for overall survival (hazard ratio: 1.39, 95% CI = 1.10-1.75;
p < 0.005; SuperPC score range = 5 to 5) (Figure 6B) and
event-free survival (hazard ratio: 1.53, 95% CI = 1.21-1.93;
p < 0.0002; SuperPC score range = 5 to 5) (Figure 6C). After
controlling for clinical and other known predictors (i.e., age, cyto-
genetic risk,CEBPA status,NPM1mutations, and FLT3-ITD), the
model was still found informative (multivariate Cox proportional
hazards model, hazard ratio: 1.29, 95% CI: 1.11-1.49;
p < 0.001) (Figures 6D and 6E). In order to confirm the robustness
ofDNAmethylationmarkers aspredictors of clinical outcome,we
performed 30 additional random splits of the data set into
a training set of 200 patients and a test set of 144 and ran the
SuperPC algorithm with a common set of parameters for all 30
runs. Under these stringent conditions in which the parameters
were not individually selected for the optimal threshold in each
run, 26 of the 30 runs validated with a significant p value of <
0.05 in a Cox proportional hazards regression model (Table S7).
These results demonstrate that DNA methylation status of indi-
vidual genes can help predict the future survival of the AML
patient, and suggest that DNA methylation biomarkers should
be evaluated alongside other predictors in futuremodel develop-
ment and evaluation studies.DISCUSSION
This comprehensive and large-scale study of DNA methylation
profiles associated with 14.000 genes in a human disease
demonstrates that epigenetic patterning distributes into signa-
tures of biological and clinical significance and that DNAmethyl-
ation classifiers can be derived from population studies with
clinical predictive power. From the biological standpoint, these
data offer an opportunity to better understand the mechanisms
through which hematopoietic cells undergo leukemogenesis.
Much effort has been invested in identifying genetic lesions
that cooperate with known recurrent translocations such as
t(8;21), t(15;17) and inv(16) or in patients with normal karyotype
leukemia. Although this effort has led to the identification of
bona fide leukemogenic mutations such as those in CEBPA,
FLT3, and NPM1, it now appears that recurrent genetic lesions
insufficiently explain the biological diversity of clinical AML. In
contrast, our data show that epigenetic lesions are abundant
and common, raising the possibility that a number of the onco-
genic lesions in AML could be epigenetic in nature. Thus, further
research exploring the contribution of genes affected by aber-
rant DNA methylation seems warranted.
The clinical significance of DNA methylation profiles is under-
lined by the fact that it contributes to identifying groups of
patients that share a common clinical outcome, in some cases
even beyond what their cytogenetic class is, such as the case
of cluster 3 leukemias. This cluster, which was enriched for
t(8;21) patients, included others without this cytogenetic marker,
however, there was no difference in survival between the two
subgroups. Although some of the patients negative for the
t(8;21) presented other cytogenetic and molecular indicators of
favorable risk, this finding reflects the existence of a common
DNAmethylation profile for these patients. This epigenetic signa-
ture aggregated these leukemias together beyond the presence
of othermolecular and cytogeneticmarkers, and in addition iden-
tified additional cases that did not present with any favorable risk
indicator. Similarly, a hypermethylated gene signature defines
a subset of leukemias with CEBPA silencing due to hypermethy-
lation, T cell lineage infidelity, resistance to myeloid growth
factors, and a poor prognosis (Figueroa et al., 2009b). These
cases formed cluster 10 in this cohort. AMLs with mutations on
bothCEBPA alleles or with homozygousmutationswere recently
shown to have ahighly favorable prognosis (Wouters et al., 2009),
and these cases also presented with a defining DNAmethylation
profile. Taken together, these data warrant considering both of
these subtypes as distinct leukemia diseases that should be as-
signed to risk stratified therapy regimens and explored for the
development of specific targeted therapy.
NPM1mutations distributed to four related but slightly distinct
signatures. These epigenetic variations cannot be explained by
the presence or absence of a concurrent FLT3-ITD, suggesting
that other as yet unrecognized mechanisms might be at play in
determining these different epigenetic groups. We were unable
to identify a DNA methylation signature associated with FLT3
lesions, indicating that mutations of this gene do not exert their
effects in AML by imposing an aberrant epigenetic pattern.
One of the notable findings of this study was the identification
of five methylation signatures with no other common morpho-
logic or molecular features, but with distinct clinical outcomes,Cancer Cell 17, 13–27, January 19, 2010 ª2010 Elsevier Inc. 19
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Figure 3. DNA Methylation Captures Clinically Significant Differences among AML Patients
(A) Left: Kaplan-Meier curves for overall survival for the favorable risk clusters 1 (inv(16)) and 4 (CEBPA-dm), and the novel epigenetically defined clusters. For
plotting simplicity curves for clusters 3 (t[8;21]), cluster 5 and cluster 15were not included in the plot. Figure S3 shows aKaplan-Meier plot including all the clusters
in the overall survival analysis. Right: Kaplan-Meier curves for overall survival for the favorable risk clusters 1 (inv[16]) and 4 (CEBPA-dm), and the NPM1 clusters.
For plotting simplicity, curves for clusters 3 (t[8;21]) and NPM1 cluster 14 were not included in the plot. Figure S3 shows a Kaplan-Meier plot including all the
clusters in the overall survival analysis.
(B) Kaplan-Meier curves for overall survival (left) for the five novel clusters. Right: Table summarizing the multivariate Cox proportional hazards regression model,
using cluster 1 (inv[16]) as the referent cluster. Additional Kaplan Meier plots are shown in Figure S3.
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DNA Methylation Profiles in AMLsuggesting that these too are unique forms of AMLwith their own
biological characteristics. It is particularly significant that these
AML subtypes cannot be identified by any available diagnostic
method, underlining that epigenetic signatures provide a critical
layer of additional information. The fact that these cases
included both normal karyotype leukemias as well as those
with cytogenetic lesions and across multiple FAB subtypes
supports amove away from definitions rooted in standard karyo-Figure 2. Distinct DNA Methylation Signatures Define each of the 16 C
Heatmap representation of the aberrant DNA methylation signatures of specific c
from healthy donors. Each row of the heatmap represents one probe set of the HE
bars) or a healthy donor (denoted by dark brown bars). (A) DNA methylation signa
associated with abnormalities of CEBPA, (C) DNA methylation signatures for clu
epigenetically defined clusters. The complete information for each cluster is contyping, rather toward a more functional classification of AML.
Future studies will be required to explore the biological basis
of these epigenetically defined subtypes in the effort to develop
risk-adapted and molecular targeted clinical trials that more
accurately reflect interindividual differences among leukemia
patients. However, the presence of a strong hypermethylated
signature in some of these clusters (clusters 2, 7, and 15)
(Figure 2D) along with their unfavorable prognosis leads us tolusters
lusters compared with a cohort of normal CD34+ hematopoietic cells obtained
LP array, and each column represents an AML patient (denoted by light brown
tures for clusters with recurrent translocations, (B) DNA methylation signatures
sters presenting NPM1 mutations, (D) DNA methylation signatures for the five
tained in Table S3.
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Figure 4. Pathway Analysis for the Epigenetically Defined Clusters
(A) Top scoring aberrantly expressed gene networks for each of the five epigenetically defined clusters. Genes overexpressed comparedwith normal CD34+ cells
are colored in red, whereas downregulated genes appear in green.
(B) Comparative analysis of the most significantly deregulated canonical pathways of the five epigenetically defined clusters as captured by an integration of the
aberrant epigenetic and gene expression signatures.
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Figure 5. 45 Genes Are Consistently Aberrantly Methylated in AML
(A) Heatmap representation of the common 45 gene signature consistently aberrantly methylated in AML. Each row represents a probe set from the HELPmicro-
array and each column represents a sample.
(B) Boxplots of gene expression levels in 4 representative genes from the 45 gene common epigenetic signature demonstrating downregulation of expression in
the AML samples compared with normal CD34+ cells. The list of genes is shown in Table S4.
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Figure 6. A DNA Methylation Classifier Predicts Clinical Outcome in AML Patients
(A) Outline describing the steps for building the DNA methylation classifier. In a first step, 200 randomly selected patients were used to identify HELP probe sets
that best predicted survival. The model was then tested on a different cohort of 95 patients (test set). Once the final model was selected, its performance in pre-
dicting survival was tested in an independent validation set consisting of 49 randomly selected cases.
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DNA Methylation Profiles in AMLspeculate that these patients, as well as those in the CEBPA-
silenced cluster, might benefit from the inclusion of hypomethy-
lating agents as part of their therapeutic regimen.
Furthermore, in this study we identified the presence of
a common DNA methylation signature that is detected in the
vast majority of cases. The nature of the genes found in this
common epigenetic signature, which included tumor suppres-
sors, putative and well-described transcription factors, nuclear
import proteins, apoptosis-related proteins, and a regulator of
myeloid cytokines, is highly suggestive of a role in leukemic
transformation. In addition, we found that this aberrant methyla-
tion was accompanied by significant downregulation of these
genes. The fact that these genes are affected in a broad fashion,
across multiple different subtypes of AML, leads us to believe
that deregulation of these genes is most likely a necessary,
though probably not sufficient, event during the malignant trans-
formation process of hematopoietic cells.
Finally, the study identified a robust 15 gene methylation clas-
sifier that was predictive of overall survival, which was generated
in an unbiased manner using a large enough data set to perform
training, testing, and independent validation. The methylation
predictor was further validated as an independent risk factor in
a multivariate analysis. Because DNA is stable and readily
obtained from clinical specimens, we believe that this DNA
methylation classifier could serve as a clinically useful biomarker
used for decision-making in future clinical trials. In conclusion,
although epigenetic deregulation has been recognized as a hall-
mark of cancer for some time, the use of epigenomics to further
expand our understanding of the biology of these diseases has
only more recently become feasible in the clinical context.
Here we show that DNA methylation profiling is a powerful tool
for the clinical stratification of AML and to further explore and
define the biology of this disease.EXPERIMENTAL PROCEDURES
Patient Samples
We made use of 344 AML cases collected at Erasmus University Medical
Center (Rotterdam) between 1990 and 2008 for which sufficient patient mate-
rial was available (Valk et al., 2004; Verhaak et al., 2009). Patients had been
treated on study protocols of the Dutch-Belgian Hemato-Oncology Coopera-
tive Group (HOVON) (available at http://www.hovon.nl). Patients in the HO04/
A, HO29, and HO42 trials received standard backbone AML treatment and no
significant survival difference has been found between these slightly different
treatments. The HO43 therapy protocol included patients over 60 years of age
and showed a more adverse outcome with increasing age as a prognostic
confounder, and for this reason we have included age as a covariable in our
statistical analyses. Samples were processed as previously described (Valk
et al., 2004; Verhaak et al., 2009). A total of 165 of the patients in this study(B) Kaplan-Meier curves for overall survival for the predicted groups in the ind
an independent validation set that were predicted either alive or deceased by
ratio = 1.39, 95% CI = 1.10, 1.75).
(C) Kaplan-Meier curves for event-free survival for the predicted groups in the ind
an independent validation set that were predicted either alive or deceased by the
1.53, 95% CI = 1.21, 1.93).
(D) Kaplan-Meier curves for overall survival for the predicted groups in the com
between patients in the combined test and independent validation sets that
(Cox Proportional hazards p < 0.000003, hazard ratio: 1.34, 95% CI = 1.18, 1.51
(E) Multivariate Cox proportional hazards regression model for the DNA methyla
mutations. For additional information please see Tables S5, S6, S7, and S8, as wwere included in the 285 patient cohort studied by gene expression by Valk
et al. (2004), and the methylation status of 16 patients was previously reported
in a publication by our group (Figueroa et al., 2009b). Median follow-up time
based on survivors was 71 months (range: 7 months to 215 months). Table 1
summarizes patients’ characteristics, Table S1 shows detailed information
for each patient, and Table S2 summarizes treatment information for each
cluster. Eight normal bone marrow CD34+ cell specimens were obtained
from the Translational Trials Development and Support Laboratory, Cincinnati
Children’s Hospital (Cincinnati, OH) and Allcells (Emeryville, CA). This research
was approved by the institutional review boards at Weill Cornell Medical
College and Erasmus University Medical Center, and written donor informed
consent was obtained in accordance with the Declaration of Helsinki.DNA Methylation Microarrays
High-molecular-weight DNA was isolated from mononuclear cell fractions
consisting of > 90% blasts using a standard high salt procedure. The HELP
assay was carried out as previously described (Khulan et al., 2006; Figueroa
et al., 2009a) and samples were hybridized onto a custom human promoter
array covering 25,626 HpaII amplifiable fragments (>50,000 CpGs), annotated
to 14,000 genes (Roche NimbleGen, Design name: 2006-10-26_
HG17_HELP_Promoter, Design ID: 4802). HpaII amplifiable fragments (HAF)
are defined as genomic regions contained between two flanking HpaII restric-
tion sites that are found between 200 and 2000 bp apart. HAF were first real-
igned to the HG18 build of the human genome and then annotated to the near-
est transcription start site (TSS), allowing for a maximum distance of 5 kb from
the TSS. Hybridization and normalization steps are described as supplemen-
tary methods. All microarray data are available from the GEO repository (Edgar
et al., 2002) (accession number GSE18700).Gene Expression Microarrays
Gene expression data for these patients had been previously published
by Verhaak et al. (2009) (GEO accession number: GSE6891). Briefly, gene
expression data were obtained using Affymetrix Human Genome 133
Plus2.0 GeneChips. mRNA isolation, labeling, hybridization, and quality
control were carried out as described previously (Valk et al., 2004). Raw
data were processed using the GC-RMA package (version 2.16.0) from
BioConductor (Wu and Irizarry).Microarray Data Analysis
Statistical analysis was performed using R 2.8.1 (Team, 2008) and BioConduc-
tor (Gentleman et al., 2004). Unsupervised hierarchical clustering of HELP data
was performed using the subset of probe sets (n = 3745) with standard devi-
ation > 1 across all cases. We used 1- Pearson correlation distance, followed
by a Lingoes transformation of the distance matrix to a Euclidean one (Chessel
et al., 2004) and subsequent clustering using Ward’s method. Clusters were
considered to be representative of a given molecular or cytogenetic finding
when > 50% of cases were positive and a two-sided Fisher’s test was signif-
icant at p < 0.05 after adjusting for multiple testing using the Bonferroni
method. Identification of the aberrant DNA methylation signature for each
cluster was performed using an ANOVA test, with correction for multiple
testing according to the Benjamini-Hochberg method, followed by Dunnett’s
post hoc test using the normal CD34+ samples as the reference group (Hot-
horn et al., 2008). Only genes with adjusted p < 0.05 and an absolute differenceependent validation set. Overall survival was compared between patients in
the DNA methylation classifier. (Cox proportional hazards p < 0.005, hazard
ependent validation set. Event-free survival was compared between patients in
DNA methylation classifier (Cox proportional hazards p < 0.0002, hazard ratio:
bined test and independent validation sets. Overall survival was compared
were predicted either alive or deceased by the DNA methylation classifier.
).
tion predictor, age, cytogenetic risk, NPM1 mutation, FLT3-ITD and CEBPA
ell as supplementary R scripts.
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DNA methylation) were selected for each cluster.
Quantitative DNA Methylation Sequencing by MassARRAY
EpiTYPER
Validation of HELP data was performed by matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry using EpiTYPER by MassARRAY
(Sequenom, San Diego, CA) on bisulfite-converted DNA as previously
described (Ehrich et al., 2005). MassARRAY primers were designed as previ-
ously described (Figueroa et al., 2009b) (see Supplemental Experimental
Procedures for primer sequences).
Pathway Analysis
Ingenuity Pathway Analysis software (Redwood City, CA) was used to perform
pathway analysis of relevant gene signatures. The top-scoring networks were
identified for the gene expression signatures of the epigenetically defined clus-
ters. A comparative analysis of the canonical pathways deregulated in each of
the clusters, as captured by the integration of the DNA methylation and gene
expression signatures, was also performed. Enrichment for specific pathways
was determined relative to the Ingenuity knowledge database using a
Benjamini-Hochberg adjusted Fisher’s test, at a significance level of adjusted
p < 0.05.
Survival Analysis
Kaplan-Meier survival analysis for overall survival was performed to compare
survival differences between different groups of clusters. A multivariate Cox
proportional hazards regression model was constructed for the including
age, cytogenetic risk, NPM1 mutation status, FLT3-ITD mutation status, and
cluster membership as the variables to be tested. Detailed description of
the model is found as supplementary methods. All survival analyses were
performed in SAS Version 9.2 (SAS Institute, Inc., Cary, NC) and Stata Version
10.0 (StataCorp, College Station, TX).
Development of an Epigenetic Predictive Model for Overall Survival
in AML
In order to develop a prognostic biomarker model predictive of AML overall
survival we used the supervised principal components (SuperPC) algorithm
developed by Bair and Tibshirani (2004). The data set was randomly divided
into three groups: a training set (n = 200), a test set (n = 95), and the remaining
49-patient cohort to be used as the independent validation set. Table S6
summarizes the patient characteristics for each of the three groups. Table
S8 shows the clinical outcome for each patient in the cohort. A detailed
description of the model training, testing and independent validation proce-
dures, as well as the R script used can be found as Supplemental Experimental
Procedures.
ACCESSION NUMBERS
All microarray data have been deposited in the Gene Expression Omnibus
(GEO) repository from the National Center for Biotechnology Information
(NCBI) with the accession code GSE18700.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight tables, and three figures, and can be found with this article online at
doi:10.1016/j.ccr.2009.11.020.
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